Adipotide (often abbreviated FTPP in the literature when referring to the full targeting–proapoptotic construct) has been used in laboratory research as a ligand-directed peptidomimetic to probe adipose vascular biology. This article summarizes the published literature themes, experimental models, mechanistic topics investigators have pursued, and important terminology that appears in primary sources. The content is strictly for research-only education and does not provide any guidance for human use.
What is adipotide (FTPP)?
In published reports, adipotide refers to a synthetic peptide construct that combines a white adipose tissue (WAT)-homing motif with a proapoptotic peptide sequence. The construct was developed as a research tool to target molecular markers on adipose vasculature and to examine consequences of selective endothelial perturbation in experimental systems. Adipotide is described in discovery-stage and translational preclinical studies as a ligand-directed bioconjugate rather than an approved therapeutic.
How adipotide appears in the research literature
Early discovery work used in vivo phage-display screening to identify a cyclic peptide motif that localized to WAT vasculature. That targeting ligand was chemically linked to a d-enantiomer proapoptotic peptide (commonly reported as D(KLAKLAK)2 or KLA) to produce the adipotide construct used in subsequent laboratory studies. Primary reports frame prohibitin (PHB/PHB1) as a vascular marker implicated in adipose-targeting experiments and present adipotide-type constructs as prototypes for vascular-targeted approaches in preclinical models (see published sources below).
Major study areas and model types
Published literature on adipotide and related constructs spans several research themes and model systems:
- Discovery and targeting: In vivo phage-display and biochemical studies to identify adipose-homing peptide motifs and to map vascular markers such as prohibitin (PHB) linked to peptide localization.
- Rodent preclinical models: Diet-induced obesity (DIO) and other rodent models are commonly used to evaluate biodistribution, tissue localization, and histological outcomes following exposure to adipotide-type constructs.
- Nonhuman primate translational work: Select studies have reported use of Old World nonhuman primates to provide translational preclinical context, with imaging-based endpoints and safety observations documented as part of laboratory research.
- Delivery and formulation science: Comparative preclinical studies examine how nanoparticle encapsulation, bioconjugates, or other delivery formats alter biodistribution and off-target profiles for the KLA proapoptotic motif.
- Mechanistic cell biology: Investigations into endothelial surface proteins (for example, PHB and interacting partners such as annexin A2) to understand target accessibility and molecular interactions in adipose endothelium.
Mechanisms investigated in the literature
Researchers have explored several mechanistic questions related to adipotide-type constructs:
- Target recognition: Studies describe how cyclic peptide motifs recognize molecular markers on adipose endothelium and the role of prohibitin (PHB/PHB1) in mediating peptide localization.
- Proapoptotic activity at the endothelium: The KLA proapoptotic motif is used in vitro and in vivo to induce mitochondrial membrane perturbation and apoptosis in targeted endothelial cells, providing a tool to study vascular contribution to adipose biology.
- PHB–ANX2 interactions: Cell-biology-focused reports investigate PHB1 interactions with annexin A2 (ANX2) and the implications for fatty-acid handling and endothelial biology in WAT.
- Off-target and safety signals in preclinical models: Translational studies document laboratory observations such as renal proximal tubule effects in nonhuman primate studies and examine reversibility and dose-dependence as part of safety profiling in research contexts.
Key terms readers may encounter
- Phage display: A screening technique used to identify peptide ligands that bind selectively to tissue targets in living animals.
- Prohibitin (PHB/PHB1): A mitochondrial and membrane-associated protein reported as a vascular marker in adipose endothelium in several studies.
- D(KLAKLAK)2 (KLA): A d-enantiomer proapoptotic peptide sequence frequently used in conjugates to induce cellular membrane perturbation and apoptosis in targeted cells in laboratory experiments.
- Biodistribution: Laboratory assessments of where a peptide construct accumulates in an experimental animal model.
- Preclinical translational study: Research using animal models intended to explore mechanistic questions and inform potential future lines of investigation, not clinical use.
Representative findings (research-context phrasing)
Selected primary reports describe (1) identification of a WAT-homing peptide motif and construction of a targeting–proapoptotic conjugate in rodent discovery studies, (2) imaging and histological laboratory observations in nonhuman primate experiments, and (3) comparisons of delivery formats affecting biodistribution in DIO mouse models. These observations are presented in the original publications as preclinical data used to investigate mechanistic hypotheses and translational questions under controlled laboratory conditions.
Limits of the published research
Several limitations appear across the literature and are commonly acknowledged by the authors:
- Most studies are preclinical and use laboratory animal models; published reports emphasize translational context rather than clinical validation.
- Mechanistic open questions remain about target specificity, the molecular basis of surface PHB accessibility, and potential off-target interactions across species.
- Delivery format and formulation significantly influence biodistribution and safety observations in experimental systems, highlighting the need for careful laboratory controls when interpreting findings.
- Reported safety observations in animal models (for example, renal proximal tubule effects in nonhuman primate studies) are described within research contexts and do not establish safety for human use.
Why research-only language matters
Using research-only language (for example, “published literature has explored” or “preclinical models show”) clarifies that summaries are descriptive of laboratory findings and not recommendations for clinical or human use. This distinction helps maintain scientific accuracy and regulatory compliance when communicating about experimental compounds and preclinical data.
Sources and further reading
Readers interested in primary sources can consult the following peer-reviewed publications and public-access articles linked in the references below for experimental details and original datasets.
For methodology details, raw data, and laboratory controls, please refer to the cited publications and to institutional repositories associated with those studies. The links in the external sources section lead to the original articles and open-access copies where available.
Related Peptide Titans Resources
Research Sources
Primary references and source materials used for this research-focused overview:
- pubmed.ncbi.nlm.nih.gov/15133506
- pmc.ncbi.nlm.nih.gov/articles/PMC3666164
- pubmed.ncbi.nlm.nih.gov/23871959
- pmc.ncbi.nlm.nih.gov/articles/PMC4959783
Frequently Asked Questions
What experimental models are most commonly used to study adipotide (FTPP)?
Published research commonly uses rodent models (including diet-induced obesity models) and select nonhuman primate models to study biodistribution, histology, and translational laboratory endpoints. Mechanistic cell and molecular biology experiments are also reported in vitro.
Does the literature identify a molecular target for adipotide-type constructs?
Several studies identify prohibitin (PHB/PHB1) as a vascular-associated marker implicated in adipose-homing peptide localization. Mechanistic reports also examine interacting proteins such as annexin A2 (ANX2) to provide context for endothelial surface accessibility in adipose tissue.
Are there safety observations reported in preclinical studies?
Preclinical translational reports document laboratory observations that investigators have interpreted as safety-relevant in animal models—for example, dose-dependent effects on renal proximal tubule markers in nonhuman primate studies. Such observations are part of research reporting and are not clinical safety determinations.
Where can I find the original publications for further reading?
Primary sources are available via PubMed and PMC links cited in the references. Those articles contain detailed methods, experimental controls, and data that are essential for laboratory researchers evaluating the work.